Royal Liverpool & Broadgreen University Hospitals NHS Truts   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Liverpool United Kingdom (1995)

Organization Overview

First Clinical Trial
1998
NCT00025441
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Liverpool Hospital | Liverpool University Hospitals NHS Foundation Trust | Royal Liverpool and Broadgreen University Hospitals NHS Trust | Royal Liverpool Children's Hospital, Alder Hey | Royal Liverpool Hospital UK | Royal Liverpool University Hospital

Active Ingredients

Drugs in Phase 4 Trials (5)

ferric carboxymaltose (Injectafer) (1 trial)

fumaric acid esters (1 trial)

live attenuated influenza virus vaccine (Flumist) (1 trial)

pneumococcal 7-valent conjugate vaccine (Prevnar) (1 trial)

sodium fluoride (18F) (1 trial)

Drugs in Phase 3 Trials (16)

capecitabine (xeloda) (1 trial)

clarithromycin (biaxin) (1 trial)

cyclophosphamide (cytoxan) (3 trials)

dasatinib (sprycel) (1 trial)

fludarabine (fludara) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (2 trials)

gv 1001 (1 trial)

imatinib (gleevec) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

leucovorin (1 trial)

nitisinone (orfadin) (2 trials)

prednisone (meticorten) (3 trials)

rituximab (rituxan) (2 trials)

sargramostim (leukine) (3 trials)

vincristine (oncovin) (5 trials)

Drugs in Phase 2 Trials (30)

acit-1 (1 trial)

alemtuzumab (campath) (1 trial)

aluminum hydroxide (Gaviscon) (1 trial)

autologous hematopoietic stem cells (2 trials)

budesonide (rhinocort) (1 trial)

cannabidiol (Epidiolex) (1 trial)

carboplatin (paraplatin) (2 trials)

ciprofloxacin (cipro) (1 trial)

cisplatin (platinol) (2 trials)

dactinomycin (cosmegen) (1 trial)

doxorubicin (Doxil) (2 trials)

doxycycline (vibramycin) (1 trial)

epirubicin (ellence) (1 trial)

etoposide (vepesid) (1 trial)

evx-02 (1 trial)

gen-004 (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

ibuprofen (motrin) (1 trial)

ifosfamide (ifex) (1 trial)

infliximab (remicade) (1 trial)

lomustine (2 trials)

methylprednisolone (medrol) (1 trial)

Molnupiravir (1 trial)

netazepide (1 trial)

nitazoxanide (Alinia) (1 trial)

sodium chloride (1 trial)

thiotepa (1 trial)

tramadol (Ultram) (1 trial)

vir-7831 (1 trial)

vir-7832 (1 trial)

Drugs in Phase 1 Trials (4)

awz1066s (1 trial)

chf10067 (1 trial)

raltegravir (isentress) (1 trial)

rifampin (1 trial)

Drugs in Other Trials (9)

acipimox (1 trial)

bleomycin (blenoxane) (1 trial)

chlorambucil (Leukeran) (2 trials)

dacarbazine (dtic-dome) (1 trial)

gip (1-42) (1 trial)

procarbazine (matulane) (2 trials)

teicoplanin (1 trial)

ubiquinone (1 trial)

vinblastine (velban) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alkaptonuria (Phase 3)

Atrophy (Phase 2)

Carcinoid Tumor (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Crohn Disease (Phase 3)

Encephalitis (Phase 3)

Eye Neoplasms (Phase 2)

Gastritis (Phase 2)

Gastritis, Atrophic (Phase 2)

Influenza, Human (Phase 4)

Intestinal Neoplasms (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Chronic-Phase (Phase 3)

Lymphoma (Phase 3)

Lymphoma, Follicular (Phase 3)

Medulloblastoma (Phase 2)

Melanoma (Phase 2)

Meningitis (Phase 4)

Nervous System Neoplasms (Phase 2)

Neuroectodermal Tumors (Phase 2)

Neuroectodermal Tumors, Primitive (Phase 2)

Ochronosis (Phase 3)

Pancreatic Neoplasms (Phase 3)

Pancreatitis (Phase 2)

Pneumococcal Infections (Phase 4)

Pneumonia (Phase 4)

Pneumonia, Pneumococcal (Phase 2)

Rhabdomyosarcoma (Phase 2)

Sarcoma (Phase 2)

Tuberculosis (Phase 1)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 36
  • # of Trial APIs: 64